Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Efficacy and Safety Study of Bevacizumab (Avastin®) in Combination With XELOX (Oxaliplatin Plus Xeloda®) for the First-line Treatment of Patients With Metastatic Cancer of the Colon or Rectum - 'OBELIX'

NCT00577031 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00577031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00577031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Efficacy and Safety Study of Bevacizumab (Avastin®) in Combination With XELOX (Oxaliplatin Plus Xeloda®) for the First-line Treatment of Patients With Metastatic Cancer of the Colon or Rectum - 'OBELIX'
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
February 29, 2008
Completion date
August 31, 2011
Enrollment
205 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer